review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | P A Wolf | |
J H Chesebro | |||
E K Massin | |||
R M Zusman | |||
A Comerota | |||
J R Hartmann | |||
E Raps | |||
P2860 | cites work | The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results | Q24514937 |
Clinical Practice Guidelines – Directions for a New Program | Q26829971 | ||
Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group | Q28165346 | ||
Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group | Q28261623 | ||
Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group | Q28284523 | ||
Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 | ||
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study | Q33396916 | ||
Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states | Q33449857 | ||
Aspirin as an antiplatelet drug | Q34338650 | ||
Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration | Q70378598 | ||
The association of changes in physical-activity level and other lifestyle characteristics with mortality among men | Q70544602 | ||
The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group | Q71394626 | ||
Antiplatelet therapy | Q71396795 | ||
Primary prevention of stroke | Q71523317 | ||
The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group | Q71523386 | ||
Clinical recommendations using levels of evidence for antithrombotic agents | Q71732636 | ||
Antithrombotic therapy in peripheral arterial occlusive disease | Q71732692 | ||
Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories | Q71916382 | ||
Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation | Q71930733 | ||
Subclinical Disease as an Independent Risk Factor for Cardiovascular Disease | Q71974433 | ||
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study | Q72171512 | ||
Does aspirin consumption affect the presentation or severity of acute myocardial infarction? | Q72341929 | ||
Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group | Q73156505 | ||
Aspirin in the treatment and prevention of cardiovascular disease | Q73324280 | ||
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group | Q73396117 | ||
Antiplatelet effect of ticlopidine after coronary stenting | Q73407496 | ||
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group | Q73422585 | ||
Practice guidelines and prediction rules should be subject to careful clinical testing | Q73453473 | ||
Are we mortgaging the medical profession? | Q95814757 | ||
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents | Q34374902 | ||
The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials | Q34403671 | ||
The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke | Q34462070 | ||
A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group | Q34540010 | ||
Basic data concerning associated coronary disease in peripheral vascular patients | Q36448743 | ||
The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 | ||
The pathogenesis of coronary artery disease and the acute coronary syndromes (2). | Q36730913 | ||
Randomised trial of prophylactic daily aspirin in British male doctors | Q36894287 | ||
A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly | Q39457551 | ||
The appropriateness of carotid endarterectomy | Q39631966 | ||
Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects | Q40412076 | ||
Antithrombotic therapy for cerebrovascular disorders. An update | Q40412158 | ||
New antithrombotics | Q40412169 | ||
Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. | Q40414451 | ||
Medical compared with surgical treatment of asymptomatic carotid artery stenosis | Q40421830 | ||
Platelets and Platelet Inhibitors in Acute Myocardial Infarction | Q40430459 | ||
Antiplatelet drugs. A comparative review | Q40432300 | ||
Pharmacokinetic optimisation of the treatment of embolic disorders | Q40504534 | ||
Drugs and surgery in the prevention of ischemic stroke | Q40561483 | ||
Antithrombotic agents in cerebral ischemia | Q40598000 | ||
Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations | Q40618389 | ||
Aspirin, platelets, and thrombosis: theory and practice. | Q40716424 | ||
New thoughts on strategies for modulating platelet function through the inhibition of surface receptors | Q40924350 | ||
Antiplatelet therapy and the prevention of thrombosis | Q41067846 | ||
Ticlopidine or clopidogrel as alternatives to aspirin in prevention of ischemic stroke | Q41158313 | ||
New developments in antiplatelet and antithrombotic therapy | Q41162547 | ||
Acute stroke therapies | Q41169631 | ||
The relation between systematic reviews and practice guidelines | Q41551981 | ||
Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. | Q42195944 | ||
European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke | Q42551725 | ||
Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content | Q42578006 | ||
Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty | Q43589719 | ||
Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group | Q43622066 | ||
Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). | Q44493271 | ||
Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase | Q44955459 | ||
Evidence-based disease management | Q46621850 | ||
Mortality over a period of 10 years in patients with peripheral arterial disease | Q46786119 | ||
Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. | Q48094539 | ||
Cerebral ischemia and asymptomatic coronary artery disease: a prospective study of 83 patients | Q48278309 | ||
Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. | Q50594716 | ||
Detailed diagnoses and procedures, National Hospital Discharge Survey, 1995. | Q50914202 | ||
An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study. | Q51556185 | ||
Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. | Q52523874 | ||
Development of aspirin resistance in persons with previous ischemic stroke. | Q54189504 | ||
Aspirin in coronary heart disease. The Coronary Drug Project Research Group | Q67242605 | ||
States of insulin resistance: the interaction between hypertension, glucose intolerance, and coronary heart disease. Proceedings of a symposium. Montreal, Canada, June 24, 1990 | Q68294900 | ||
Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group | Q68323492 | ||
RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 | Q69755626 | ||
Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin | Q69875861 | ||
Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications | Q70212920 | ||
A prospective study of aspirin use and primary prevention of cardiovascular disease in women | Q70215146 | ||
P433 | issue | 9 | |
P304 | page(s) | 559-573 | |
P577 | publication date | 1999-09-01 | |
P1433 | published in | Clinical Cardiology | Q4502312 |
P1476 | title | Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection | |
P478 | volume | 22 |